Japan IVD Point of Care Testing Market, Key Company Profiles, Market Dynamics and Recent Developments - Forecast to 2030

The Japan IVD Point of Care (POC) Testing market is predicted to surpass US$ 700 Million by 2030, from around US$ 450 Million in 2025. Japan represents one of the largest and most technologically advanced In Vitro Diagnostics (IVD) Point-of-Care (POC) Testing markets in the Asia-Pacific region. The market is driven by the country's rapidly aging population, increasing prevalence of chronic and infectious diseases, and strong emphasis on delivering timely, decentralized diagnostic services. Japan's well-established healthcare infrastructure, universal health insurance system, and widespread adoption of advanced diagnostic technologies have accelerated the integration of POCT solutions across hospitals, clinics, emergency departments, pharmacies, nursing homes, and home healthcare settings.

Within the Japanese IVD market, POCT has become an essential component of clinical diagnostics by enabling rapid test results at or near the site of patient care, thereby reducing turnaround time and facilitating immediate treatment decisions. Demand is particularly strong for blood glucose monitoring, HbA1c testing, blood gas analysis, cardiac biomarkers, urinalysis, infectious disease diagnostics, and critical care point-of-care platforms.

The market is further supported by Japan's growing focus on home healthcare and community-based medical services, creating opportunities for portable, user-friendly diagnostic devices designed for chronic disease management and elderly patient care. In addition, the integration of POCT instruments with laboratory information systems (LIS), electronic medical records (EMR), and digital healthcare platforms is improving workflow efficiency and enhancing clinical decision-making.

Domestic manufacturers such as ARKRAY Inc., FUJIFILM Healthcare, and Terumo Corporation, along with global players including Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher - Radiometer, and Becton Dickinson, continue to invest in product innovation and molecular diagnostic technologies to strengthen their market presence.

Recent Developments

• In July 2026, Roche introduced the cobas HDV test for use on the cobas 5800/6800/8800 systems, a diagnostic tool for the detection and quantification of Hepatitis D Virus (HDV) RNA, in countries accepting the CE mark. Available on the industry-leading cobas 5800/6800/8800 systems, Roche aims to help healthcare providers in identifying patients and monitoring their care more effectively alongside newly available treatments.
• In April 2025, H.U. Group Holdings, Inc. and its wholly-owned subsidiary Fujirebio Holdings, Inc. announced that the Global Health Innovative Technology (GHIT) Fund has awarded a two-year, approximately $4.5 million grant to Fujirebio’s wholly-owned subsidiary, Fluxus, Inc., to develop an ultrasensitive point-of-care (POC) urine test for tuberculosis (TB). The test will utilize Fluxus’ novel single-molecule counting technology, with the potential to be used for both pulmonary and extrapulmonary TB in all patient populations.
• In June 2023, Sysmex Corporation announced the launch of the world's first point-of-care testing system that detects antimicrobial susceptibility within 30 minutes. Designed for urinary tract infections, the system utilizes innovative microfluidic technology to provide rapid results, enhancing antimicrobial use and addressing the urgent global threat of antimicrobial resistance (AMR).

By Segment: Japan IVD Point of Care (POC) Testing Market - Key Takeaways

• POC Infectious Diseases represents the largest segment in the Japan IVD POCT market, driven by the country's aging population, high burden of seasonal respiratory infections, and the need for rapid clinical decision-making. Hospitals, emergency departments, and outpatient clinics increasingly rely on point-of-care infectious disease tests to enable early diagnosis and immediate treatment, reducing hospital stays and unnecessary antibiotic use.
• Denka holds a leading position in Japan's IVD POC Infectious Diseases market, underpinned by its comprehensive portfolio of rapid diagnostic solutions for respiratory and other infectious diseases. Roche and Tauns Laboratories are among the other major players in Japan's IVD POC Infectious Diseases market. Roche leverages its global expertise in molecular diagnostics and advanced POCT platforms, while Tauns has established a strong domestic presence through innovative infectious disease assays tailored to the needs of Japanese healthcare providers.
• POC Blood Gas & Electrolytes is the second-largest segment in Japan's IVD POCT market, driven by its critical role in emergency medicine, intensive care units (ICUs), operating rooms, and neonatal care. Rapid assessment of blood gases, electrolytes, and acid-base balance enables timely clinical decision-making for critically ill patients, improving treatment outcomes.
• Danaher-Radiometer is the leading player in Japan's POC Blood Gas & Electrolytes market, driven by its technologically advanced blood gas analyzers, strong installed base in hospitals, and broad adoption across emergency, critical care, and intensive care settings. Siemens Healthineers follows closely, leveraging its integrated diagnostic platforms and strong relationships with acute care providers. Techno Medica and Abbott are also key market participants, supported by reliable point-of-care analyzers, continuous product innovation, and expanding adoption in hospitals and decentralized healthcare settings.
• POC Urinalysis represents another significant segment of Japan's IVD POCT market, driven by the high prevalence of chronic kidney disease, diabetes, urinary tract infections (UTIs), and the growing demand for rapid routine screening in hospitals and clinics. Eiken Chemical leads the market with its strong domestic product portfolio and extensive presence across Japanese healthcare institutions, while ARKRAY and Siemens Healthineers are other key players, leveraging advanced urinalysis technologies, continuous product innovation, and well-established distribution networks.
• POC Chemistry & HbA1c is another significant segment of Japan's IVD POCT market, driven by the rising prevalence of diabetes, an aging population, and increasing demand for rapid metabolic monitoring in hospitals and outpatient settings. Point-of-care HbA1c and chemistry testing enables faster diagnosis, treatment optimization, and improved chronic disease management while enhancing clinical workflow efficiency. Fujifilm leads the segment with its strong portfolio of point-of-care chemistry analyzers and extensive domestic market presence, while ARKRAY, Siemens Healthineers, and FUJIFILM Wako are other major players, competing through advanced diagnostic technologies, continuous product innovation, and well-established distribution networks.
• POC Cardiac represents an important segment of Japan's IVD POCT market, driven by the growing burden of cardiovascular diseases, a rapidly aging population, and the need for rapid diagnosis in emergency and critical care settings. Fukuda Denshi leads the segment through its strong domestic presence, specialized cardiovascular diagnostic portfolio, and extensive hospital network, reinforcing its leadership in Japan's point-of-care cardiac diagnostics market.
• POC Critical Care is an important segment of Japan's IVD POCT market, encompassing biomarkers such as C-reactive protein (CRP) and Procalcitonin (PCT), which are essential for the rapid assessment of severe infections, sepsis, and systemic inflammation. Demand is driven by the need for immediate clinical decision-making in intensive care units (ICUs), emergency departments, and acute care settings, where timely diagnosis can significantly improve patient outcomes.

The report titled “Japan IVD Point of Care (POC) Testing Market (By Segment: POC Cardiac, POC Bloodgas & Electrolytes, POC Urinalysis, POC Hospital Glucose (connected to LIS), POC Chemistry + HbA1c, POC Patient Monitoring / Coagulation, POC Infectious Diseases, POC Critical Care, POC Others), Key Company Profiles, Market Dynamics and Recent Developments - Forecast to 2030” provides a comprehensive analysis of the Japan IVD Point of Care (POC) Testing Market.

This report has been analyzed from 15 View Points:

• Japan - IVD Point of Care (POC) Testing Market & Forecast (2021-2030)
• By Segment - Japan IVD Point of Care (POC) Testing Market Share & Forecast (2021-2030)
• By Company - Japan IVD Point of Care (POC) Testing Market Share & Forecast (2021-2030)
• Japan - POC Cardiac Market & Forecast (2021-2030)
• Japan - POC Bloodgas & Electrolytes Market & Forecast (2021-2030)
• Japan - POC Urinalysis Market & Forecast (2021-2030)
• Japan - POC Hospital Glucose (connected to LIS) Market & Forecast (2021-2030)
• Japan - POC Chemistry + HbA1c Market & Forecast (2021-2030)
• Japan - POC Patient Monitoring / Coagulation Market & Forecast (2021-2030)
• Japan - POC Infectious Diseases Market & Forecast (2021-2030)
• Japan - POC Critical Care Market & Forecast (2021-2030)
• Japan - POC Others Market & Forecast (2021-2030)
• Japan IVD Point of Care (POC) Testing Market - Recent Developments
• Japan IVD Point of Care (POC) Testing Market - Key Company Profiles
• Japan IVD Point of Care (POC) Testing - Market Dynamics

By Segment: Japan IVD Point of Care (POC) Testing Market & Forecast

1. POC Cardiac Market

• Troponin
• BNP
• Pro-BNP
• Other POC Cardiac

2. POC Bloodgas & Electrolyte

3. POC Urinalysis

4. POC Hospital Glucose (connected to LIS)

5. POC Chemistry + HbA1c

• POC Chemistry
• POC HbA1c

6. POC Patient Monitoring / Coagulation

7. POC Infectious Diseases

• HIV
• STD
• Hepatitis
• VBD
• Gastrointestinal
• Respiratory

8. POC Critical Care

• CRP
• PCT

9. POC Others

Japan IVD Point of Care (POC) Testing Market - Key Company Profiles

• Denka
• Roche
• Danaher - Radiometer
• D.S. Pharma
• Siemens
• Becton Dickinson
• Techno Medica
• EIKEN CHEMICAL
• Fujifilm
• Fujifilm - Wako
• Fujirebio
• Fukuda Denshi
• LSI Medience
• Sekisui
• Abbott
• Werfen - Instrumentation Laboratory
• Horiba ABX - Horiba
• Arkray
• Sanwa
• Terumo
• Nipro
• Nihon Kohden
• Nissui
• Minaris
• Mizuho
• Toyobo
• SD Biosensor
• Nova Biomedical
• Alfresa Pharma
• TAUNS
• Nippon Gene
• Otsuka